Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 4.84 USD
Market Cap: 625.6m USD
Have any thoughts about
Exscientia PLC?
Write Note

Exscientia PLC
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exscientia PLC
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Exscientia PLC
NASDAQ:EXAI
Depreciation & Amortization
ÂŁ15.6m
CAGR 3-Years
125%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Depreciation & Amortization
$810k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Depreciation & Amortization
$6.6m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Depreciation & Amortization
$7.1m
CAGR 3-Years
75%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Depreciation & Amortization
ÂŁ4.1m
CAGR 3-Years
-23%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Depreciation & Amortization
ÂŁ46.9m
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
15%
No Stocks Found

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.88 USD
Undervaluation 1%
Intrinsic Value
Price

See Also

What is Exscientia PLC's Depreciation & Amortization?
Depreciation & Amortization
15.6m GBP

Based on the financial report for Dec 31, 2023, Exscientia PLC's Depreciation & Amortization amounts to 15.6m GBP.

What is Exscientia PLC's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 3Y
125%

Over the last year, the Depreciation & Amortization growth was 33%. The average annual Depreciation & Amortization growth rates for Exscientia PLC have been 125% over the past three years .

Back to Top